Kite, A Gilead Company, And Arcellx Have Expanded Their Existing Collaboration, Which Was Originally Announced In December 2022, For CART-ddBCMA To Include Lymphomas; Arcellx To Receive $200M Equity Investment And $85M Upfront Cash Payment
Portfolio Pulse from Benzinga Newsdesk
Kite, a subsidiary of Gilead Sciences, and Arcellx have broadened their collaboration on CART-ddBCMA, initially announced in December 2022, to now include lymphomas. Arcellx will receive a $200M equity investment and an $85M upfront cash payment from Kite.
November 15, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcellx benefits from an expanded collaboration with Kite, receiving a significant $200M equity investment and $85M in cash, which could accelerate its research and development efforts.
The financial infusion from Kite provides Arcellx with substantial resources to advance its CART-ddBCMA program, particularly in lymphomas. This deal not only validates Arcellx's technology but also provides the capital necessary to potentially expedite the development process. Investors are likely to react positively to this news, anticipating accelerated progress and a stronger position in the competitive oncology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Gilead Sciences, through its subsidiary Kite, has expanded its collaboration with Arcellx, which could enhance its oncology portfolio and potentially lead to future revenue growth.
The expansion of the collaboration with Arcellx signifies Gilead's commitment to strengthening its oncology pipeline, which is likely to be viewed positively by investors. The substantial financial investment indicates a strong belief in the potential of the CART-ddBCMA technology, which could lead to significant advancements in lymphoma treatment and, consequently, revenue growth for Gilead.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80